The Lancet. Oncology

publication venue for

Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial. 2024
First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial.. 24. 2023
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study.. 24. 2023
Health-related quality of life and pain outcomes with [¹⁷⁷Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial.. 24. 2023
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study.. 24. 2023
MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study.. 23. 2022
Genetic predisposition to cancer across people of different ancestries in Qatar: a population-based, cohort study. 2022
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study. 2022
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study.. 22. 2021
The impact of scaling up access to treatment and imaging modalities on global disparities in breast cancer survival: a simulation-based analysis.. 22. 2021
Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial.. 22. 2021
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.. 22. 2021
Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study.. 21. 2020
Estimating the impact of treatment and imaging modalities on 5-year net survival of 11 cancers in 200 countries: a simulation-based analysis.. 21. 2020
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial.. 21. 2020
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.. 21. 2020
Neuroleptic strategies for terminal agitation in patients with cancer and delirium at an acute palliative care unit: a single-centre, double-blind, parallel-group, randomised trial.. 21. 2020
First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.. 21. 2020
Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial.. 21. 2020
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.. 21. 2020
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.. 21. 2020
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.. 21. 2020
Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study.. 21. 2019
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.. 21. 2019
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.. 21. 2019
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial.. 21. 2019
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.. 20. 2019
Comparison of the accuracy of human readers versus machine-learning algorithms for pigmented skin lesion classification: an open, web-based, international, diagnostic study.. 20. 2019
Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.. 20. 2019
Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.. 20. 2019
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.. 20. 2019
Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial.. 20. 2019
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.. 20. 2019
Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial.. 20. 2019
Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.. 19. 2018
Temporal patterns in the risk of chronic health conditions in survivors of childhood cancer diagnosed 1970-99: a report from the Childhood Cancer Survivor Study cohort.. 19. 2018
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.. 19. 2018
Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study.. 19. 2018
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.. 19. 2018
Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial.. 19. 2018
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.. 19. 2018
Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study.. 19. 2018
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.. 19. 2017
Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.. 18. 2017
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.. 18. 2017
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.. 18. 2017
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.. 18. 2017
Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.. 18. 2017
Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial.. 18. 2017
Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis.. 18. 2016
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.. 18. 2016
Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data.. 18. 2016
Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.. 17. 2016
Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.. 17. 2016
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial.. 17. 2016
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.. 17. 2016
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.. 17. 2016
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.. 17. 2016
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial.. 17. 2016
Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.. 17. 2016
Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial.. 17. 2016
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.. 17. 2016
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.. 17. 2016
Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.. 17. 2016
Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.. 17. 2016
Pregnancy after chemotherapy in male and female survivors of childhood cancer treated between 1970 and 1999: a report from the Childhood Cancer Survivor Study cohort.. 17. 2016
Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis.. 17. 2016
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.. 17. 2016
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.. 17. 2016
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.. 17. 2016
Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.. 17. 2016
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.. 17. 2015
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.. 16. 2015
Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial.. 16. 2015
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.. 16. 2015
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.. 16. 2015
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.. 16. 2015
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.. 16. 2015
Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial.. 16. 2015
Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial.. 16. 2015
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.. 16. 2015
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.. 16. 2015
Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.. 16. 2015
Stereotactic radiosurgery alone for brain metastases.. 16. 2015
PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study.. 16. 2015
Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).. 16. 2015
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.. 16. 2015
Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.. 16. 2015
Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial.. 16. 2014
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.. 15. 2014
Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial.. 15. 2014
Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.. 15. 2014
Cumulative alkylating agent exposure and semen parameters in adult survivors of childhood cancer: a report from the St Jude Lifetime Cohort Study.. 15. 2014
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.. 15. 2014
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.. 15. 2014
Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial.. 15. 2014
Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.. 15. 2014
Risk of late effects of treatment in children newly diagnosed with standard-risk acute lymphoblastic leukaemia: a report from the Childhood Cancer Survivor Study cohort.. 15. 2014
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.. 15. 2014
Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial.. 15. 2014
Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.. 15. 2014
Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.. 15. 2014
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.. 15. 2014
Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial.. 15. 2014
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.. 15. 2013
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial.. 14. 2013
Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis.. 14. 2013
Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial.. 14. 2013
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.. 14. 2013
Infertility, infertility treatment, and achievement of pregnancy in female survivors of childhood cancer: a report from the Childhood Cancer Survivor Study cohort.. 14. 2013
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.. 14. 2013
Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.. 14. 2013
The conundrum of clinical trials in adult germ-cell tumours.. 14. 2013
Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study.. 14. 2012
Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial.. 13. 2012
A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study.. 13. 2012
Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study.. 13. 2012
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.. 13. 2012
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.. 13. 2012
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.. 13. 2012
Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial.. 13. 2012
Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.. 13. 2012
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.. 13. 2012
Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial.. 13. 2011
Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.. 12. 2011
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.. 12. 2011
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.. 12. 2011
Effect of dignity therapy on distress and end-of-life experience in terminally ill patients: a randomised controlled trial.. 12. 2011
Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study.. 12. 2011
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.. 11. 2010
External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.. 11. 2010
Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data.. 11. 2010
Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis.. 11. 2010
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.. 11. 2010
Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials.. 11. 2010
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.. 11. 2009
Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis.. 10. 2009
The surgical learning curve for laparoscopic radical prostatectomy: a retrospective cohort study.. 10. 2009
Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data.. 10. 2009
Where observation is concerned, chance favours only the prepared mind.. 9. 2008
Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study.. 8. 2007
Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial.. 8. 2007
Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy.. 8. 2007
Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.. 8. 2007
Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study.. 7. 2006
Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study.. 7. 2006
Ivosidenib for advanced IDH1-mutant cholangiocarcinoma - Authors' reply.. 21. 2020
Multidisciplinary care in tenosynovial giant cell tumours.. 20. 2019
Precision oncology giveth and precision oncology taketh away.. 20. 2019
A well organised effort to metastatic non-clear-cell renal cell carcinoma.. 20. 2019
Ramucirumab and the controversial role of α-fetoprotein in hepatocellular carcinoma.. 20. 2019
Changing the standard of care for treating melanoma brain metastases.. 19. 2019
TOMAS: revisiting PARP inhibitor combination therapy.. 19. 2018
The brim of uncertainty in adjuvant treatment of melanoma.. 19. 2018
Antibody-drug conjugates: can the payload improve activity in HER2 expressing cancers?. 18. 2017
Reduced-dose ipilimumab with standard-dose pembrolizumab: is less more?. 18. 2017
A step forward for patients with NRAS-mutant melanoma.. 18. 2017
Immune therapy meets precision medicine.. 18. 2017
Looking back, moving forward: the evolution of cancer survivorship care.. 18. 2017
Hemithoracic radiotherapy for mesothelioma: lack of benefit or lack of statistical power?. 17. 2016
Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma.. 17. 2015
Busulfan-based conditioning regimens: not all partners are equal.. 16. 2015
PET-adapted salvage therapy for Hodgkin's lymphoma--authors' reply.. 16. 2015
Who should receive EGFR tyrosine-kinase inhibitors?. 13. 2012
Biomarkers in personalised treatment of renal-cell carcinoma.. 13. 2012
Keynote comment: are large-scale cancer-genomics projects ready to use?. 7. 2006
Effect of dose-intensive chemotherapy on quality of life.. 6. 2005
Do systemic cancer treatments affect cognitive function?. 5. 2004
Time for a shift in molecular down staging in luminal breast cancer. 2019
Inflammatory breast cancer: a new approach. 2016
Circulating tumour cells: telling the truth about metastasis. 2014
Screening for breast cancer brain metastases. 2022
Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC. 2022
Glioma patient-reported outcome assessment in clinical care. 2020
PCI in resected small-cell lung cancer. 2016
Whole-brain radiotherapy in primary CNS lymphoma. 2011
Focused attention on brain metastases. 2009
A silver lining on the horizon for glioblastoma. 2009
Early or delayed radiotherapy for low-grade glioma? 2005
Volume in dose escalation for malignant glioma--bigger might be better. 2005
Medical imaging and nuclear medicine: a Lancet Oncology Commission. 2021
Sebaceous carcinoma: evidence-based clinical practice guidelines. 2019
Optimising efficacy and reducing toxicity of anticancer radioimmunotherapy. 2019
Future cancer research priorities in the USA: a Lancet Oncology Commission. 2017
Proton therapy for head and neck cancer: expanding the therapeutic window. 2017
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. 2017
Histiocytoses: emerging neoplasia behind inflammation. 2017
Response assessment after stereotactic body radiotherapy for spinal metastasis: a report from the SPIne response assessment in Neuro-Oncology (SPINO) group. 2015
Global cancer surgery: delivering safe, affordable, and timely cancer surgery. 2015
Nomograms in oncology: more than meets the eye. 2015
Translational implications of somatic genomics in acute myeloid leukaemia. 2014
Breast cancer in Arab populations: molecular characteristics and disease management implications. 2013
Molecular diagnostics in paediatric glial tumours. 2013
Management of colon cancer: resource-stratified guidelines from the Asian Oncology Summit 2012. 2012
Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy. 2012
Treatment implications of the emerging molecular classification system for melanoma. 2011
Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. 2010
Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. 2010
Surviving childhood and reproductive-age malignancy: effects on fertility and future parenthood. 2010
Systemic effects of local radiotherapy. 2009
Exercise intolerance in cancer and the role of exercise therapy to reverse dysfunction. 2009
Nosocomial infections in patients with cancer. 2009
Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. 2008
Cardiorespiratory exercise testing in clinical oncology research: systematic review and practice recommendations. 2008
Diet, exercise, and complementary therapies after primary treatment for cancer. 2006
Management of Pancoast tumours. 2006
Rare uterine cancers. 2005
Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. 2004
Prostate cancer: a dynamic illness with shifting targets. 2003
Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. 2001
Hepatic-arterial chemotherapy. 2001
New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer. 2001
Unconventional therapies for cancer and cancer-related symptoms. 2001
Vaccines for melanoma: translating basic immunology into new therapies. 2001
Management of soft-tissue sarcomas: an overview and update. 2000
Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer. 2024
Global Cancer Surgery: pragmatic solutions to improve cancer surgery outcomes worldwide. 2023
National Cancer Institute Collaborative Workshop on Shaping the Landscape of Brain Metastases Research: challenges and recommended priorities. 2023
Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop. 2023
Recurrence-free survival versus overall survival as a primary endpoint for studies of resected colorectal liver metastasis: a retrospective study and meta-analysis. 2022
Imaging response assessment for CNS germ cell tumours: consensus recommendations from the European Society for Paediatric Oncology Brain Tumour Group and North American Children's Oncology Group. 2022
Dosimetry in radionuclide therapy: the clinical role of measuring radiation dose. 2022
Radiotheranostics: a roadmap for future development. 2020
Liver resection for metastatic colorectal cancer in the presence of extrahepatic disease. 2009
Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. 2018

VIVO Weill Cornell Medical College

The Lancet. Oncology Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)